EP 1603949 B9 20110202 - ANTIBODIES AGAINST HUMAN IL-21 RECEPTOR AND USES THEREFOR
Title (en)
ANTIBODIES AGAINST HUMAN IL-21 RECEPTOR AND USES THEREFOR
Title (de)
ANTIKÖRPER GEGEN IL21-REZEPTOR UND DEREN VERWENDUNG
Title (fr)
ANTICORPS DIRIGES CONTRE LE RECEPTEUR HUMAIN DE L'IL-21 ET UTILISATIONS CORRESPONDANTES
Publication
Application
Priority
- US 2004007444 W 20040312
- US 45433603 P 20030314
Abstract (en)
[origin: WO2004083249A2] The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21 R). The antibodies can act as antagonists of IL-21 R activity, thereby modulating immune responses in general, and those mediated by IL-21 R in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.
IPC 8 full level
C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61P 37/00 (2006.01); A61P 37/06 (2006.01); C12N 5/07 (2010.01); C12N 5/078 (2010.01); C12N 5/09 (2010.01)
CPC (source: EP KR US)
A61K 39/395 (2013.01 - KR); A61P 1/00 (2018.01 - EP); A61P 1/04 (2018.01 - EP); A61P 7/00 (2018.01 - EP); A61P 17/00 (2018.01 - EP); A61P 17/06 (2018.01 - EP); A61P 19/02 (2018.01 - EP); A61P 19/04 (2018.01 - EP); A61P 19/08 (2018.01 - EP); A61P 25/02 (2018.01 - EP); A61P 25/28 (2018.01 - EP); A61P 29/00 (2018.01 - EP); A61P 35/00 (2018.01 - EP); A61P 37/00 (2018.01 - EP); A61P 37/02 (2018.01 - EP); A61P 37/06 (2018.01 - EP); A61P 43/00 (2018.01 - EP); C07K 16/28 (2013.01 - KR); C07K 16/2866 (2013.01 - EP US); A61K 2039/505 (2013.01 - EP US); C07K 2317/56 (2013.01 - EP US); C07K 2317/622 (2013.01 - EP US)
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
Designated extension state (EPC)
AL LT LV MK
DOCDB simple family (publication)
WO 2004083249 A2 20040930; WO 2004083249 A3 20041209; AR 043616 A1 20050803; AT E456581 T1 20100215; AU 2004221876 A1 20040930; AU 2004221876 B2 20110526; BR PI0408315 A 20060307; CA 2518371 A1 20040930; CL 2004000534 A1 20050304; CN 102040662 A 20110504; CN 1777621 A 20060524; CO 5660297 A2 20060731; DE 602004025332 D1 20100318; EP 1603949 A2 20051214; EP 1603949 B1 20100127; EP 1603949 B8 20100310; EP 1603949 B9 20110202; EP 2184298 A1 20100512; ES 2340280 T3 20100601; JP 2007525159 A 20070906; JP 4914209 B2 20120411; KR 20050119120 A 20051220; MX PA05009556 A 20051116; NO 20054170 D0 20050907; NO 20054170 L 20051205; NZ 542306 A 20080430; RU 2005131852 A 20060420; US 2004265960 A1 20041230; US 2010297151 A1 20101125; US 7495085 B2 20090224; US 8143385 B2 20120327; ZA 200507067 B 20061227
DOCDB simple family (application)
US 2004007444 W 20040312; AR P040100859 A 20040315; AT 04720349 T 20040312; AU 2004221876 A 20040312; BR PI0408315 A 20040312; CA 2518371 A 20040312; CL 2004000534 A 20040315; CN 200480010518 A 20040312; CN 201010165730 A 20040312; CO 05093185 A 20050914; DE 602004025332 T 20040312; EP 04720349 A 20040312; EP 09178337 A 20040312; ES 04720349 T 20040312; JP 2006507081 A 20040312; KR 20057017254 A 20050914; MX PA05009556 A 20040312; NO 20054170 A 20050907; NZ 54230604 A 20040312; RU 2005131852 A 20040312; US 35381209 A 20090114; US 79838004 A 20040312; ZA 200507067 A 20050902